Clinical evaluation of non-narcotic substitutive effects produced by ANAR during the therapy of patients with heroin abuse.
The substitutive effects of potentiated ANAR (affinely purified antibodies to morphine hydrochloride in dilutions C30 and C200) used to relieve the opium withdrawal syndrome in 149 patients with heroin abuse were studied in an open standardized clinical trial. Over the first 2 days of therapy the preparation produced the vegetostabilizing, sedative, anxiolytic, neuroprotective, and moderate analgetic effects. During the therapy of patients with opium intoxication ANAR delayed the appearance of symptoms for the opium withdrawal syndrome by 18-30 h. This phenomenon allows us to shorten the period of urgent therapy and decrease doses of symptomatic drugs. Our results show that ANAR possesses substitutive properties and may be used to relieve the opium withdrawal syndrome and post-withdrawal disorders resulting from heroin abuse in remission.
Krylov
E N
EN
Moscow Institute of Psychiatry, Russian Ministry of Health.
D000328:Adult; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006556:Heroin Dependence / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009020:Morphine / Q000276:immunology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D000906:Antibodies; D009020:Morphine